N/A
Completed N=67
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
Source: ClinicalTrials.gov NCT01106976 ↗Enrolled (actual)
67
Serious AEs
0.0%
Results posted
Feb 2016
Primary outcomePrimary: AChE PET Neuroimaging — 0.0238; 0.0226 1/min — p=0.0009
Summary
The purpose of this research is to evaluate changes in cholinergic brain activity over time in subjects with Parkinson disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY AChE PET Neuroimaging |
0.0238; 0.0226 | 0.0009 sig |
Eligibility Criteria
Inclusion Criteria
- Patients who meet the UK Parkinson's Disease Society Brain Bank Research Center clinical diagnostic criteria for PD.
- Hoehn and Yahr stages 1-2.5 at initial recruitment in baseline study.
- Absence of dementia confirmed by neuropsychological testing at initial recruitment in baseline study.
Exclusion Criteria
- contra-indication for magnetic resonance study
- Pregnancy or breastfeeding
Data sourced from ClinicalTrials.gov (NCT01106976). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.